261 related articles for article (PubMed ID: 33402486)
1. Prognostic Factors in Hormone-sensitive Prostate Cancer Patients Treated With Combined Androgen Blockade: A Consecutive 15-year Study at a Single Japanese Institute.
Miyazawa Y; Sekine Y; Arai S; Oka D; Nakayama H; Syuto T; Nomura M; Koike H; Matsui H; Shibata Y; Suzuki K
In Vivo; 2021; 35(1):373-384. PubMed ID: 33402486
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of multiple androgen receptor signaling inhibitor medicines with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a study in the real world.
Lu Y; Jiang J; Yang G; Ding H; Zheng Q; Ji L; Wang Y; Dong Z; Zhai Z; Tian J; Zhang Y; Wang J; Yang L; Wang Z
Front Oncol; 2024; 14():1324181. PubMed ID: 38699643
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Abiraterone and Combined Androgen Blockade Therapy for High-Risk Metastatic Hormone-Sensitive Prostate Cancer: A Propensity Score-Matched Analysis.
Matsumura N; Fujita K; Nishimoto M; Yamamoto Y; Kuwahara K; Nagai Y; Minami T; Hatanaka Y; Nozawa M; Morimoto Y; Tahara H; Uejima S; Esa A; Hirayama A; Yoshimura K; Uemura H
Front Oncol; 2021; 11():769068. PubMed ID: 34993133
[TBL] [Abstract][Full Text] [Related]
4. Clinical Outcomes of Patients with High-risk Metastatic Hormone-naïve Prostate Cancer: A 3-year Interim Analysis of the Observational J-ROCK Study.
Miyake H; Matsumoto R; Fujimoto K; Mizokami A; Uemura H; Kamoto T; Kawakami S; Nakamura K; Maekawa S; Shibayama K; Watanabe A; Ito M; Tajima Y; Matsuyama H; Uemura H
Eur Urol Oncol; 2024 Jun; 7(3):625-632. PubMed ID: 38296736
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value of the pretreatment lung immune prognostic index in patients with metastatic hormone-sensitive and castration-resistant prostate cancer.
Wang Z; Liu H; Zhao J; Chen J; Zhu S; Dai J; Ni Y; Xu N; Zhao F; He B; Zhang X; Liang J; Sun G; Liu Z; Shen P; Zeng H
Ann Transl Med; 2023 Mar; 11(5):201. PubMed ID: 37007568
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes and nadir prostate-specific antigen (PSA) according to initial PSA levels in primary androgen deprivation therapy for metastatic prostate cancer.
Kitagawa Y; Ueno S; Izumi K; Kadono Y; Mizokami A; Hinotsu S; Akaza H; Namiki M
World J Urol; 2016 Mar; 34(3):319-27. PubMed ID: 26089252
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of Abiraterone Acetate Plus Prednisolone and Combined Androgen Blockade in High-risk Metastatic Hormone-Sensitive Prostate Cancer].
Yasukawa H; Ikehata Y; Tsuboi Y; Nishiyama N; Watanabe A; Fujiuchi Y; Kitamura H
Hinyokika Kiyo; 2020 Dec; 66(12):427-432. PubMed ID: 33435652
[TBL] [Abstract][Full Text] [Related]
8. Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high-risk metastatic hormone-sensitive prostate cancer.
Yanagisawa T; Kimura T; Mori K; Suzuki H; Sano T; Otsuka T; Iwamoto Y; Fukuokaya W; Miyajima K; Enei Y; Sakanaka K; Matsukawa A; Onuma H; Obayashi K; Tsuzuki S; Hata K; Shimomura T; Miki J; Egawa S
Prostate; 2022 Jan; 82(1):3-12. PubMed ID: 34559410
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
10. A territory-wide real-world efficacy and toxicity analysis of abiraterone acetate versus docetaxel in 574 Asian patients with metastatic hormone-sensitive prostate cancer.
Lam BHW; Tsang VHM; Lee MP; Chan K; Liu TC; Ng BYH; Wo BBW; Leung KC; Mui WH; Chan TW; Lam MHC; Siu SWK; Poon DMC
Clin Genitourin Cancer; 2024 Feb; 22(1):e75-e85.e1. PubMed ID: 37604745
[TBL] [Abstract][Full Text] [Related]
11. Impact of pretreatment anemia on upfront abiraterone acetate therapy for metastatic hormone-sensitive prostate cancer: a multicenter retrospective study.
Okamoto T; Noro D; Hatakeyama S; Narita S; Mitsuzuka K; Sakurai T; Kawamura S; Hoshi S; Shimoda J; Tanaka T; Kawaguchi T; Ishidoya S; Ito A; Tsuchiya N; Habuchi T; Ohyama C
BMC Cancer; 2021 May; 21(1):605. PubMed ID: 34034691
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes and prognostic factors in patients with newly diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy: a retrospective multicenter study in Japan.
Narita S; Hatakeyama S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Sato H; Koizumi A; Mitsuzuka K; Tochigi T; Tsuchiya N; Ohyama C; Arai Y; Nomura K; Habuchi T
Int J Clin Oncol; 2020 May; 25(5):912-920. PubMed ID: 31919691
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis.
Fallara G; Robesti D; Nocera L; Raggi D; Marandino L; Belladelli F; Montorsi F; Malavaud B; Ploussard G; Necchi A; Martini A
Cancer Treat Rev; 2022 Nov; 110():102441. PubMed ID: 35939976
[TBL] [Abstract][Full Text] [Related]
14. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).
Francini E; Gray KP; Xie W; Shaw GK; Valença L; Bernard B; Albiges L; Harshman LC; Kantoff PW; Taplin ME; Sweeney CJ
Prostate; 2018 Sep; 78(12):889-895. PubMed ID: 29707790
[TBL] [Abstract][Full Text] [Related]
15. Characteristics and progression-free survival of Afro-Caribbean men with metastatic hormone-sensitive prostate cancer at the time of diagnosis.
Rossignol T; Gourtaud G; Senechal C; Sadreux Y; Roux V; Blanchet P; Brureau L
Prostate; 2021 Oct; 81(14):1091-1096. PubMed ID: 34320690
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel chemotherapy plus androgen-deprivation therapy in high-volume disease metastatic hormone-sensitive prostate cancer in Chinese patients: an efficacy and safety analysis.
Guo Z; Lu X; Yang F; Qin L; Yang N; Wu J; Wang H
Eur J Med Res; 2022 Aug; 27(1):148. PubMed ID: 35953852
[TBL] [Abstract][Full Text] [Related]
17. Tumor cytoreduction results in better response to androgen ablation--a preliminary report of palliative transurethral resection of the prostate in metastatic hormone sensitive prostate cancer.
Qin XJ; Ma CG; Ye DW; Yao XD; Zhang SL; Dai B; Zhang HL; Shen YJ; Zhu Y; Zhu YP; Shi GH; Xiao WJ; Lin GW; Swanson GP
Urol Oncol; 2012; 30(2):145-9. PubMed ID: 20451424
[TBL] [Abstract][Full Text] [Related]
18. Apalutamide versus bicalutamide in combination with androgen deprivation therapy for metastatic hormone sensitive prostate cancer.
Ueda T; Shiraishi T; Miyashita M; Kayukawa N; Gabata Y; Sako S; Ogura R; Fujihara A; Okihara K; Ukimura O
Sci Rep; 2024 Jan; 14(1):705. PubMed ID: 38184704
[TBL] [Abstract][Full Text] [Related]
19. Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis.
Wenzel M; Würnschimmel C; Nocera L; Collà Ruvolo C; Tian Z; Shariat SF; Saad F; Briganti A; Tilki D; Graefen M; Kluth LA; Roos FC; Mandel P; Chun FKH; Karakiewicz PI
Eur Urol Focus; 2022 Mar; 8(2):399-408. PubMed ID: 33853754
[TBL] [Abstract][Full Text] [Related]
20. An exploratory retrospective multicenter study of prognostic factors in mCRPC patients undergoing enzalutamide treatment: Focus on early PSA decline and kinetics at time of progression.
Miyazawa Y; Sekine Y; Shimizu N; Takezawa Y; Nakamura T; Miyao T; Nakayama H; Kurihara S; Syuto T; Nomura M; Koike H; Matsui H; Shibata Y; Suzuki K
Prostate; 2019 Sep; 79(12):1462-1470. PubMed ID: 31334872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
